Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Nokia shares fall despite earnings beat on cash flow concerns
Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $63 at Jefferies
March 5, 2025 5:21 AM ESTJefferies analyst Amy Li lowered the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $63.00 (from $64.00) while maintaining a Buy rating.
The analyst comments "BHVN provided program updates during Q4 earnings. Our thoughts - BHV-1300: While we see +'ves in data (~80% median... More
Piper Sandler Reiterates Overweight Rating on Biohaven Pharmaceutical Holding (BHVN)
March 3, 2025 12:35 PM ESTPiper Sandler analyst Christopher J. Raymond reiterated an Overweight rating and $76.00 price target on Biohaven Pharmaceutical Holding (NYSE: BHVN).
The analyst comments "Remain OW rated on BHVN shares following a Q424 update and the announcement of additional P1 MAD data for IgG... More



